25,000 Shares in Anteris Technologies Global Corp (NASDAQ:AVR) Acquired by Maven Securities LTD

Maven Securities LTD bought a new position in Anteris Technologies Global Corp (NASDAQ:AVR) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 25,000 shares of the company’s stock, valued at approximately $140,000. Maven Securities LTD owned about 0.07% of Anteris Technologies Global as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Millennium Management LLC acquired a new stake in Anteris Technologies Global in the 4th quarter worth approximately $1,748,000. Ensign Peak Advisors Inc acquired a new position in shares of Anteris Technologies Global during the fourth quarter worth approximately $5,801,000. Cantor Fitzgerald L. P. acquired a new position in shares of Anteris Technologies Global during the fourth quarter worth approximately $227,000. Citadel Advisors LLC acquired a new position in shares of Anteris Technologies Global during the fourth quarter worth approximately $1,160,000. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Anteris Technologies Global during the fourth quarter worth approximately $3,069,000.

Anteris Technologies Global Price Performance

Shares of AVR stock opened at $4.10 on Thursday. Anteris Technologies Global Corp has a 12 month low of $2.34 and a 12 month high of $8.79. The stock’s 50 day simple moving average is $4.40.

Anteris Technologies Global (NASDAQ:AVR) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.61) EPS for the quarter. Equities analysts anticipate that Anteris Technologies Global Corp will post -2.66 earnings per share for the current fiscal year.

About Anteris Technologies Global

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.